CD274 and non-small cell lung carcinoma: To date, PD-L1 detection by immunohistochemistry is the only companion test approved by the FDA for immune checkpoint inhibition in non-small cell lung cancer (NSCLC), urothelial carcinoma, cervical cancer, and triple-negative breast cancer.